Biblio Discovery — Demo Discovery Service

74 results for "null null"

Showing 61–74 · 2.03 seconds · RSS

  1. Journal Article Full text

    Role of CYP2B in Phenobarbital-Induced Hepatocyte Proliferation in Mice

    Li, Lei; Bao, Xiaochen; Zhang, Qing-Yu et al.

    Drug Metab Dispos · 2017 · English · PubMed Central

    …proliferation. This hypothesis was tested here by using a Cyp2a(4/5)bgs-null (null) mouse model in which all Cyp2b genes are deleted. Adult male and female wild-type (WT) and null mice were treated intraperitoneally with PB at 50 mg/kg once daily for 5 successive days and tested on day 6. The…

  2. Journal Article Full text

    How Genetic Variants in Children with Familial Hypercholesterolemia Not Only Guide Detection, but Also Treatment

    van den Bosch, Sibbeliene E.; Corpeleijn, Willemijn E.; Hutten, Barbara A. et al.

    Genes (Basel) · 2023 · English · PubMed Central

    …this medication is less potent in patients without functional LDLR (e.g., null/null variant). Novel therapies that are expected to become available in the near future focused on inhibition of another major regulatory protein in lipid metabolism (angiopoietin-like 3 (ANGPTL3)) might dramatically…

  3. Journal Article Full text

    Neutrophils as key regulators of tumor immunity that restrict immune checkpoint blockade in liver cancer

    Feng, Mei; Wang, Fangyanni; Liu, Xinyu et al.

    Cancer Biol Med · 2023 · English · PubMed Central

    …Myc and Kras(G12D) into the genome in liver cells from conditional Trp53 null/null mice (pTMK/Trp53(−/−)). Flow cytometry and immunohistochemistry were used to assess the changes in immune cells in the tumor microenvironment. An ex vivo coculture assay was performed to test the inhibitory effects…

  4. Journal Article Full text

    Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis

    Krishnan, Anuradha; Li, Xia; Kao, Winston Whei-Yang et al.

    Lab Invest · 2012 · English · PubMed Central

    …investigate the functional role of lumican in hepatic fibrosis, lumican null (Null) and wild-type (WT) littermates were administered carbon tetrachloride intra-peritoneally. Serum and liver tissue were analyzed for indices of liver injury, fibrosis, matrix turnover, and proliferation. Hepatic…

  5. Journal Article Full text

    Cardiac aging is initiated by matrix metalloproteinase-9-mediated endothelial dysfunction

    Yabluchanskiy, Andriy; Ma, Yonggang; Chiao, Ying Ann et al.

    Am J Physiol Heart Circ Physiol · 2014 · English · PubMed Central

    …dysfunction, we compared the LVs of 6–9- and 15–18-mo-old WT and MMP-9 null (Null) mice. All groups showed similar LV function by echocardiography, indicating that dysfunction had not yet developed in the older group. Myocyte nuclei numbers and cross-sectional areas increased in both WT and Null…

  6. Journal Article Full text

    Alpha 1-antitrypsin deficiency caused by the alpha 1-antitrypsin Nullmattawa gene. An insertion mutation rendering the alpha 1-antitrypsin gene incapable of producing alpha 1-antitrypsin.

    Curiel, D; Brantly, M; Curiel, E et al.

    J Clin Invest · 1989 · English · PubMed Central

    …the development of pulmonary emphysema. An alpha 1AT gene is defined as "Null" when no alpha 1AT in serum is attributed to that alpha 1AT gene. Although all alpha 1AT Null genes have identical phenotypic consequences (i.e. no detectable alpha 1AT in the serum), different genotypic mechanisms can…

  7. Journal Article Full text

    Evaluation of "at risk" alpha 1-antitrypsin genotype SZ with synthetic oligonucleotide gene probes.

    Nukiwa, T; Brantly, M; Garver, R et al.

    J Clin Invest · 1986 · English · PubMed Central

    …1AT genes. However, when used to evaluate a very rare family carrying a null allele, these four oligonucleotide probes misidentified the "at risk" null-null and S null phenotypes as "not at risk" MM and SM combinations. These observations indicate that oligonucleotide gene probes yielded reliable…

  8. Journal Article Full text

    Early childhood height-adjusted total kidney volume as a risk marker of kidney survival in ARPKD

    Burgmaier, Kathrin; Kilian, Samuel; Arbeiter, Klaus et al.

    Sci Rep · 2021 · English · PubMed Central

    …childhood and adolescence for the overall cohort. Patients with two null PKHD1 variants had larger first documented haeTKV values than children with missense variants (median (IQR) haeTKV 793 (450–1098) ml/m in Null/null, 403 (260–538) ml/m in Null/mis, 230 (169–357) ml/m in Mis/mis). In the…

  9. Journal Article Full text

    Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis

    Xiao, Guoguang; Gao, Shan; Xie, Yongmei et al.

    Medicina (Kaunas) · 2024 · English · PubMed Central

    …homozygous FH (HoFH), it varied dramatically. Pediatric patients with the null/null variant may respond to the treatment. PCSK9 inhibitors were generally well tolerated within most pediatric patients, in line with previous studies among adult populations. Conclusions: The PCSK9 inhibitors…

  10. Journal Article Full text

    WWOX developmental and epileptic encephalopathy: Understanding the epileptology and the mortality risk

    Oliver, Karen L.; Trivisano, Marina; Mandelstam, Simone A. et al.

    Epilepsia · 2023 · English · PubMed Central

    …WWOX variants from our cohort and the literature were coded as either null or missense, allowing individuals to be classified into one of three genotype classes: (1) null/null, (2) null/missense, (3) missense/missense. Differences in survival outcome were estimated using the Kaplan–Meier method…

  11. Journal Article Full text

    Focal adhesion kinase inhibition enhances response to checkpoint immunotherapy in hepatocellular carcinoma

    Liu, Xinyu; Wang, Fangyanni; Cui, Peng et al.

    J Transl Int Med · 2025 · English · PubMed Central

    …integration of Myc and Kras(G12D) oncogenes into hepatocytes of Trp53 null/null mice (pTMK/Trp53(-/-)), coupled with subcutaneous xenograft models. These models were treated with FAK inhibitor IN10018 as monotherapy or in combination with anti-PD-1 immunotherapy. RESULTS: FAK was highly expressed…

  12. Journal Article Full text

    Generation of a Tph2 Conditional Knockout Mouse Line for Time- and Tissue-Specific Depletion of Brain Serotonin

    Pelosi, Barbara; Pratelli, Marta; Migliarini, Sara et al.

    PLoS One · 2015 · English · PubMed Central

    …of the third exon of Tph2 gene results in the production of a Tph2 (null) allele in which we observed the near-complete loss of brain serotonin, as well as the growth defects and perinatal lethality observed in serotonin conventional knockouts. We also revealed that in mice harbouring the Tph2…

  13. Journal Article Full text

    The Effect of PCSK9 Inhibitors on LDL-C Target Achievement in Patients with Homozygous Familial Hypercholesterolemia: A Retrospective Cohort Analysis

    Alshahrani, Awad; Kholaif, Naji; Al-Khnifsawi, Mutaz et al.

    Adv Ther · 2024 · English · PubMed Central

    …EAS target LDL-C while receiving PCSK9i; genotype analysis suggested LDLR-null/null patients were most refractory to PCSK9i. CONCLUSION: Response to PCSK9i was minimal in this cohort of patients with HoFH. No patients achieved EAS LDL-C targets, and most failed to reach the EAS-recommended 15%…

  14. Journal Article Full text

    Efficacy and Safety of Inclisiran in Adolescents With Genetically Confirmed Homozygous Familial Hypercholesterolemia: Results From the Double-Blind, Placebo-Controlled Part of the ORION-13 Randomized Trial

    Wiegman, Albert; Peterson, Amy L.; Hegele, Robert A. et al.

    Circulation · 2025 · English · PubMed Central

    BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is a genetic disease characterized by high levels of low-density lipoprotein cholesterol (LDL-C) present from birth, leading to early-onset and progressive atherosclerotic cardiovascular disease. Early treatment initiation is crucial for…